Cerebrospinal α-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort
Author | Majbour, Nour K. |
Author | Abdi, Ilham Y. |
Author | Dakna, Mohammed |
Author | Wicke, Tamara |
Author | Lang, Elisabeth |
Author | Ali Moussa, Houda Y. |
Author | Thomas, Mercy A. |
Author | Trenkwalder, Claudia |
Author | Safieh-Garabedian, Bared |
Author | Tokuda, Takahiko |
Author | Mollenhauer, Brit |
Author | El-Agnaf, Omar |
Available date | 2023-03-27T07:55:53Z |
Publication Date | 2021-09-01 |
Publication Name | Movement Disorders |
Identifier | http://dx.doi.org/10.1002/mds.28611 |
Citation | Majbour, N.K., Abdi, I.Y., Dakna, M., Wicke, T., Lang, E., Ali Moussa, H.Y., Thomas, M.A., Trenkwalder, C., Safieh-Garabedian, B., Tokuda, T., Mollenhauer, B. and El-Agnaf, O. (2021), Cerebrospinal α-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort. Mov Disord, 36: 2048-2056. https://doi.org/10.1002/mds.28611 |
ISSN | 08853185 |
Abstract | Background: Tangible efforts have been made to identify biomarkers for Parkinson's disease (PD) diagnosis and progression, with α-synuclein (α-syn) related biomarkers being at the forefront. Objectives: The objectives of this study were to explore whether cerebrospinal fluid (CSF) levels of total, oligomeric, phosphorylated Ser 129 α-synuclein, along with total tau, phosphorylated tau 181, and β-amyloid 1–42 are (1) informative as diagnostic markers for PD, (2) changed over disease progression, and/or (3) correlated with motor and cognitive indices of disease progression in the longitudinal De Novo Parkinson cohort. Methods: A total of 94 de novo PD patients and 52 controls at baseline and 24- and 48-month follow-up were included, all of whom had longitudinal lumbar punctures and clinical assessments for both cognitive and motor functions. Using our in-house enzymelinked immunosorbent assays and commercially available assays, different forms of α-synuclein, tau, and β-amyloid 1–42 were quantified in CSF samples from the De Novo Parkinson cohort. Results: Baseline CSF total α-synuclein was significantly lower in early de novo PD compared with healthy controls, whereas the ratio of oligomeric/total and phosphorylated/total were significantly higher in the PD group. CSF oligomeric-α-synuclein longitudinally increased over the 4-year follow-up in the PD group and correlated with PD motor progression. Patients at advanced stages of PD presented with elevated CSF oligomeric-α-synuclein levels compared with healthy controls. Conclusions: Longitudinal transitions of CSF biomarkers over disease progression might not occur linearly and are susceptible to disease state. CSF oligomeric-α-synuclein levels appear to increase with diseases severity and reflect PD motor rather than cognitive trajectories. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
Language | en |
Publisher | Wiley |
Subject | biomarkers DeNoPa disease progression longitudinal cohort oligomers Parkinson's disease α-synuclein |
Type | Article |
Pagination | 2048 - 2056 |
Issue Number | 9 |
Volume Number | 36 |
ESSN | 1531-8257 |
Files in this item
This item appears in the following Collection(s)
-
Medicine Research [1518 items ]